
TSE:JWEL
This summary was created by AI, based on 2 opinions in the last 12 months.
Jamieson Wellness (JWEL-T) has garnered positive reviews from analysts who highlight its strong core business performance and the potential for future unsolicited takeout offers. With a solid growth trajectory, having expanded its operations into China and acquired a California company, Jamieson is well-positioned in the nutraceutical market, especially given the minimal impact from tariffs. The company has been able to consistently grow its dividend at a rate of 14% over the past five years, providing an appealing yield of 2.55%. Analysts suggest that despite the recent appreciation in stock price, the likelihood of a takeout is greater than market expectations, making it an attractive buy at this point. Overall, the sentiment from experts reflects confidence in the company's strategic direction and financial health.
To "pump up" portfolios across Canada. Founded in Windsor ON. Bought a California company a few years ago, so little to no impact from tariffs. Growing in China, where company's attention to quality makes it stand apart. Seeing takeouts of private vitamin/mineral companies at much higher valuations. Has grown dividend over last 5 years at 14% clip. Yield is 2.55%.
(Analysts’ price target is $42.43)There has been no signficant recent company news, good or bad. It recently did get some upgrades, with TD noting 'strong contributions from the Chinese market, and no negative operational news'. The decline could be general small cap aversion or tariff fears, as we cannot point to anything specific here. The last quarter was mixed, but estimates have slowly ticked up over the last month. We would consider it OK, with high debt the main drawback for us.
Unlock Premium - Try 5i Free
Huge margins and free cashflow. Growing business annually compounded at over 15%. International expansion. US acquisition is growing double digits. Online China business growing 80%. Never been cheaper at 17x forward PE. Takeover potential in a few years. Yield is 2%.
(Analysts’ price target is $40.82)EPS of 9c beat estimates of 6c; revenue of $128M beat estimates of $123.1M. EBITDA of $16M matched estimates. Year forecast was maintained. A couple of brokers lowered targets. Revenue fell 6.4% with a large decline in Strategic Partners business with the closing of a contract. Gross margins declined. While this was a 'beat' versus expectations, debt remains too high for our comfortable level, considering the fairly big decline in growth vs prior year. We think buyers can wait.
Unlock Premium - Try 5i Free
That's right. They've been severely beaten up over the last few years. Massive outflow of funds out of Canada, and it hits the smaller stocks even more. A lot of retail investors put in fund redemptions last year, so that created many bargains.
Over the last 6 months, he added to many of his small- and mid-cap positions. Companies like QTRH, JWEL, and EQB.
Canada's #1 brand in its sector, has 25% market share. Went public 6-7 years ago, and increased sales and profits every year. US acquisition should accelerate growth. Now controls direct distribution in China. Cheaper than ever at 18x earnings, but growth prospects are better than ever. High margin, high quality, steady. Great entry point. Yield is 2.32%.
(Analysts’ price target is $43.53)He sold it after a recent disappointing earnings report (lowered their guidance a lot). After all, they're not in a cyclical business. Their acquisition of a Chinese company was interesting, though the structure was unusual--they bought $100 million in preferred shares with warrants but no dividend and took a minority share in the Chinese business. That was the right move in the Chinese market. Otherwise, JWEL's fundamentals didn't impress him. The stock isn't getting much love these days.
Jamieson Wellness is a Canadian stock, trading under the symbol JWEL.TO (previously JWEL-T on Stockchase) on the Toronto Stock Exchange (JWEL-CT). It is usually referred to as TSX:JWEL or JWEL.TO
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on JWEL.TO (previously JWEL-T on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Jamieson Wellness.
Jamieson Wellness was recommended as a Top Pick by Andrey Omelchak on 2026-06-26. Read the latest stock experts ratings for Jamieson Wellness.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Jamieson Wellness.
Jamieson Wellness is followed by 152 investors on Stockchase and is a trending stock that is worth watching.
On 2026-07-15, Jamieson Wellness (JWEL.TO) stock closed at a price of $41.93.
Unsolicited takeout offer. Core business doing quite well. He'd buy, despite recent stock appreciation, as odds of a takeout are higher than the market is expecting.